AI-native biotech Insilico Medicine announced a partnership worth up to $2.5 billion at BIO 2026, betting its generative drug-discovery platform can outpace traditional pharmaceutical R&D, even as its flagship AI-designed drug has yet to clear pivotal late-stage trials.
Insilico Medicine published LongevityBench in Cell on September 17, 2026, a 17-task benchmark showing that 18 frontier AI systems from major developers all struggled with predicting biological age from molecular data, while the company's own compact Longevity-LLMs matched or beat much larger models.
The VA has used ambient AI scribes from Abridge and Knowtex in more than 986,000 primary care appointments since October 2025, with veterans opting out less than 1% of the time, and now plans a 2026 enterprise contract to expand the tools nationwide.
The FDA's December 23, 2025 clearance of UpDoc V1.0, the first patient-facing LLM cleared as a medical device, lets a chatbot guide insulin dosing for type 2 diabetes patients at Cleveland Clinic, AHN, and UCSF, but the $18 million-backed startup won't say how much the AI itself shapes the treatment decision.
The FDA's new TEMPO pilot lets four digital health companies, including Limbic's AI voice therapy agent Unpacked, reach Medicare patients and gather real-world outcomes data before seeking full marketing authorization.
Novo Nordisk announced on September 17, 2026 that it will deploy Anthropic's Claude Science across its research workflows, its second major AI drug-discovery tie-up this year after an April deal with OpenAI.
Paige, the digital pathology company acquired by Tempus in 2024, has secured FDA Breakthrough Device designation for PanCancer Detect, an AI tool that flags suspicious tissue across multiple organ sites and has already shown double-digit gains in detection accuracy in clinical testing.
Newly released documents show two vendors running CMS's AI-driven WISeR prior-authorization pilot denied more than 20,000 requests in three months, with one contractor rejecting the majority of claims it reviewed and requests going unanswered for up to 83 days.
A prospective study at Hawaii Pacific Health Medical Group found that clinicians who used the Abridge ambient AI scribe, integrated into their Epic electronic health record, saw significant drops in after-hours charting and burnout symptoms.
US telehealth nutrition company Berry Street has merged with India's Healthify, combining Healthify's AI food-logging coach Ria with Berry Street's insurance-covered dietitian network to serve the surge of patients on GLP-1 weight-loss drugs.